Powderject vows to keep bankrolling Labour
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Paul Drayson, the chairman of Powderject, vowed to continue giving money to the Labour Party despite the controversy that erupted when his company won a £32m Government contract to supply smallpox vaccine.
The company said yesterday it was heading towards a £25m profit this year, higher than analysts had been forecasting. The City believes the smallpox contract will contribute £10m to profits over the coming two or three years.
Mr Drayson has made two £50,000 donations to Labour, one in December, weeks before tendering for the smallpox contract got under way.
He maintained Powderject won the contract "fair and square" in a bidding war against four rivals. "I am a Labour supporter and I will continue to support them regularly, in an entirely personal capacity. The two things are entirely separate."
Moreover, he dismissed suggestions that he had misused his position as head of the industry lobby group, the BioIndustry Association, during the process of tendering for the smallpox contract. A BIA taskforce talked with the Government in the wake of 11 September about carrying out an audit of the industry's capacity to supply vaccines and other medicines for use in the event of a bioterrorist attack.
"Those discussions were about an exchange of information and explicitly avoided commercial discussions. All meetings took place with all 10 companies present, and I did not have any private discussions with Government."
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments